Is compounded tirzepatide still legal in 2026?
A status question with a dated answer. Here is the timeline as the FDA published it, what remains lawful, and where the open questions sit.
As of August 31, 2026:
Routine mass-market compounding of tirzepatide and semaglutide ended with the shortages that permitted it. The FDA removed tirzepatide from the drug-shortage list on October 2, 2024 and reaffirmed the decision on December 19, 2024; its enforcement-discretion windows for compounders closed on February 18, 2025 (503A pharmacies) and March 19, 2025 (503B outsourcing facilities). Semaglutide’s shortage was declared resolved on February 21, 2025, with the windows closing April 22, 2025 (503A) and May 22, 2025 (503B). Since then, lawful compounding runs through the ordinary FD&C pathways — a 503A pharmacy compounding for an individual patient on a prescription, or an FDA-registered 503B facility — and those pathways generally do not permit a product that is “essentially a copy” of an approved drug unless a prescriber documents a change that makes a significant difference for that patient. In May 2026 the FDA was reported to propose keeping tirzepatide off the 503B bulk-substances list. The programs in this database sell under those pathways; we verify their published prices and disclosures, not their legal compliance, and nothing here is legal advice.
The timeline
Shortage-era compounding of both molecules rested on one condition — the FDA shortage listing — and both listings are gone. Tirzepatide came off the list on October 2, 2024, the decision was reaffirmed on December 19, 2024 after a compounding trade group sued, and the agency’s stated enforcement-discretion windows closed on February 18, 2025 for 503A pharmacies and March 19, 2025 for 503B outsourcing facilities. Semaglutide followed: shortage declared resolved February 21, 2025, with the windows closing April 22 (503A) and May 22, 2025 (503B).
What remains lawful
The ordinary FD&C pathways: a state-licensed 503A pharmacy compounding for an individual patient on a valid prescription, and FDA-registered 503B outsourcing facilities operating under CGMP. The load-bearing limit is the “essentially a copy” rule — outside a shortage, those pathways generally do not permit a product that is essentially a copy of an approved drug unless the prescriber documents a change that makes a significant difference for that patient. That is why the market’s language shifted toward personalized dosing and combination formulations, and why the legal footing of routine compounded GLP-1s in 2026 is contested rather than settled.
2026 developments, as reported
In May 2026 the FDA was reported to propose keeping tirzepatide off the 503B bulk-substances list. Reported regulatory development; read the FDA docket before relying on it.
What this site does and does not check
We verify published prices, fees, terms and disclosures for 59 programs — including which ones name a dispensing pharmacy and what classification they state (pharmacy records). We do not adjudicate any program’s legal compliance, and none of this page is legal advice. The FDA’s own compounding pages are the primary source for the rules; a clinician and, where it matters, a lawyer are the right readers of them.
Definitions used on this page
Questions this page answers
Is compounded tirzepatide legal in 2026?
Routine mass-market compounding of tirzepatide and semaglutide ended with the shortages that permitted it. The FDA removed tirzepatide from the drug-shortage list on October 2, 2024 and reaffirmed the decision on December 19, 2024; its enforcement-discretion windows for compounders closed on February 18, 2025 (503A pharmacies) and March 19, 2025 (503B outsourcing facilities). Semaglutide’s shortage was declared resolved on February 21, 2025, with the windows closing April 22, 2025 (503A) and May 22, 2025 (503B). Since then, lawful compounding runs through the ordinary FD&C pathways — a 503A pharmacy compounding for an individual patient on a prescription, or an FDA-registered 503B facility — and those pathways generally do not permit a product that is “essentially a copy” of an approved drug unless a prescriber documents a change that makes a significant difference for that patient. In May 2026 the FDA was reported to propose keeping tirzepatide off the 503B bulk-substances list. The programs in this database sell under those pathways; we verify their published prices and disclosures, not their legal compliance, and nothing here is legal advice.
Is compounded semaglutide legal in 2026?
The same framework applies with later dates: the FDA declared the semaglutide shortage resolved on February 21, 2025 and its enforcement-discretion windows closed on April 22, 2025 (503A) and May 22, 2025 (503B). Lawful compounding since then runs through the ordinary 503A/503B pathways subject to the “essentially a copy” limit. Not legal advice.
Does a provider being in this database mean its product is legal?
No. Inclusion means the program is tracked and its published prices and disclosures are recorded to our standard. We verify prices, not legal compliance, and we say so on every provider page.